{"metadata": {"source": "pubchem", "title": "Methadone | C21H27NO | CID 4095 - PubChem", "description": "Methadone | C21H27NO | CID 4095 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/4095", "drug": "Methadone", "cid": 4095, "char_count": 207830, "word_count": 28065, "doc_id": "doc_48", "num_chunks": 289, "chunk_id": "48::chunk_6", "document_index": 48, "latency_s": 1.735201399991638, "prompt_toks": 53767, "completion_toks": 75, "relevance_score": 2.7264703e-06}, "content": "Drug: Methadone | cid: 4095\nSource: pubchem | Source description: Methadone | C21H27NO | CID 4095 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    substances that increase the risk of harm or overdose. Provision of OAT is often combined with education about harm reduction including use of clean needles and injection supplies in an effort to reduce the risks associated with injection drug use such as contraction of HIV and Hepatitis C and other complications including skin infections, abscesses, or endocarditis.\n\n\n                    Context: \n                    This excerpt appears within the section on drug and medication safety, specifically discussing harm reduction strategies associated with opioid substitution therapy (OAT) such as methadone. It highlights that provision of OAT should be accompanied by education on safe injection practices to mitigate risks like infections and overdose, emphasizing the importance of harm reduction in the overall context of opioid treatment safety and public health information.\n                "}
{"metadata": {"source": "pubchem", "title": "Oxycodone | C18H21NO4 | CID 5284603 - PubChem", "description": "Oxycodone | C18H21NO4 | CID 5284603 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5284603", "drug": "Oxycodone", "cid": 5284603, "char_count": 168604, "word_count": 22166, "doc_id": "doc_54", "num_chunks": 238, "chunk_id": "54::chunk_152", "document_index": 54, "latency_s": 1.3368932000012137, "prompt_toks": 45340, "completion_toks": 62, "relevance_score": 4.850262e-07}, "content": "Drug: Oxycodone | cid: 5284603\nSource: pubchem | Source description: Oxycodone | C18H21NO4 | CID 5284603 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    American Society of Health-System Pharmacists 2017; Drug Information 2017. Bethesda, MD. 2017, p. 2275\n\nFor more Interactions (Complete) data for Oxycodone (16 total), please visit the HSDB record page.\n\n12.1.14 Antidote and Emergency Treatment\n\n/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/\n\n\n                    Context: \n                    This excerpt provides critical information on emergency first aid procedures for oxycodone overdose, including airway management, decontamination, and CPR guidelines. It is part of the comprehensive section on safety, toxicity, and treatment protocols within the full chemical and pharmacological profile of oxycodone in the document.\n                "}
{"metadata": {"source": "erowid", "title": "Erowid Methadone Vault", "description": "Information about Methadone including basics, effects, dosage, history, legal status, photos, research, media coverage, and links to other resources.", "language": "No language found.", "url": "https://www.erowid.org/chemicals/methadone/methadone.shtml", "drug": "Methadone", "cid": 4095, "substance": "methadone", "category": "CHEMICALS", "erowid_column": "MainPage", "char_count": 5408, "word_count": 744, "doc_id": "doc_183", "num_chunks": 7, "chunk_id": "183::chunk_6", "document_index": 183, "latency_s": 0.9865222000080394, "prompt_toks": 1794, "completion_toks": 62, "relevance_score": 3.689885e-07}, "content": "Drug: Methadone | cid: 4095\nSource: erowid | Source description: Information about Methadone including basics, effects, dosage, history, legal status, photos, research, media coverage, and links to other resources.\nErowid name: methadone\nCategory: CHEMICALS\nField: MainPage\n\n                    Text: \n                    Join Together: Methadone News\n\nHEALTH #\n\nFDA Health Advisory for Methadone, Nov 27, 2006, FDA\n\nFDA: Methadone Information\n\nIncreases in Methadone-Related Deaths: 1999-2004, CDC\n\nPRESCRIPTION GUIDELINES #\n\nMethadone for Pain Guidelines CPSO (Canada)\n\nMethadone Maintenance Guidelines CPSO (Canada)\n\nMethadone Maintenance Treatment Practices Task Force (Ontario), March 2007\n\n[ back to chemicals ]\n\nCreated by Erowid - Feb 26, 1997 Modified - Nov 15, 2015\n\nContent & design © 1995-2023 Erowid.org. Permission required before publicly reproducing Erowid info.\n\n\n                    Context: \n                    This chunk appears within the \"Methadone\" section of the Erowid chemicals database, providing health advisories, official information, related overdose data, and prescription guidelines from health authorities such as the FDA and Canadian agencies, relevant for understanding methadone's medical use, risks, and regulatory context.\n                "}
